A5016787940- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
- Multiple and Secondary Primary Cancers
- HIV/AIDS drug development and treatment
- Protein Degradation and Inhibitors
- Medical Imaging Techniques and Applications
- Palliative Care and End-of-Life Issues
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Cancer survivorship and care
- Lung Cancer Diagnosis and Treatment
- Education Methods and Technologies
- Cancer Genomics and Diagnostics
- Frailty in Older Adults
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Colorectal Cancer Treatments and Studies
Kantonsspital St. Gallen
2016-2025
Swiss Group For Clinical Cancer Research
2014-2024
University of St. Gallen
2012-2024
Kantonsspital Aarau
2009-2023
University of Zurich
2020
BC Cancer Agency
2014-2016
University of British Columbia
2016
Kantonsspital Münsterlingen
2009-2015
University Hospital of Bern
2015
St. Gallen Oncology Conferences
2013
Our main objective was to prospectively determine the prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after two cycles rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-14) under standardized treatment PET evaluation criteria.Patients with any stage diffuse large B-cell lymphoma were treated six R-CHOP-14 followed by rituximab. PET/CT examinations performed at baseline, (and four if...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It characterized by the translocation t(11;14) leading to cyclin D1 over-expression. Cyclin downstream mammalian target rapamycin threonine kinase can be effectively blocked inhibitors. We set out examine single agent activity orally available inhibitor everolimus in a prospective, multicenter trial patients with relapsed or refractory mantle (NCT00516412).Eligible who had received maximum three prior...
Purpose Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of treatment remains unknown. Patients and Methods Two hundred seventy untreated, relapsed, stable, or chemotherapy-resistant lymphoma were treated four doses rituximab monotherapy weekly intervals (375 mg/m 2 ). achieving at least a partial response randomly assigned receive one infusion every months, either on short-term schedule...
Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease nelfinavir activates vitro. We determined dose-limiting toxicity and recommended dose for phase II combination with bortezomib. Twelve patients advanced hematologic malignancies were treated (2500–5000 mg/day p.o., days 1–14, 3+3 escalation) bortezomib (1.3 mg/m2, 1, 4, 8, 11; 21-day cycles). A run monotherapy allowed...
Abstract Background 18 F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore predictive relevance metabolic tumor volume (MTV) total lesion glycolysis (TLG) patients with early stage Hodgkin treated within German Study Group HD16 trial. Methods F-FDG PET/CT images were available for MTV TLG analysis 107 cases from We calculated using three different threshold methods (SUV 4.0,...
Summary Peripheral T‐cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, subset patients experience durable disease control, and little is known regarding long‐term The International Lymphoma Project (ITCLP) the largest prospectively collected cohort PTCLs, providing insight into outcomes at academic medical centres globally. We performed outcome analysis on from ITCLP available 10‐year follow‐up data ( n = 735). overall...
The optimal choice of salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or Hodgkin (HL) remains unknown. Based on promising results phase II trials, the preferred regimen in British Columbia since 2002 has been out-patient regimen, gemcitabine, dexamethasone, and cisplatin (GDP). We conducted a retrospective analysis including all DLBCL HL who received GDP as between September June 2010. identified 235 patients: 152 DLBCL, 83 HL. Overall response...
Abstract Hairy cell leukemia (HCL) remains an incurable disease. However, first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. Although there are excellent long-term data for application, similar regarding administration lacking. We therefore analyzed the outcome of 3 prospective multicenter clinical trials on performed by Swiss Group Clinical Cancer Research (SAKK), which recruited 221 patients classical HCL between 1993 and...
Abstract Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within last two decades. However, until recently, improvement overall survival (OS) was only documented younger, transplant‐eligible patients. In this analysis, we retrospectively investigated outcome of older patients with newly diagnosed MM unselected patient population a special focus on use novel agents routine care...